Skip to main content
NIH funding notice RFA-MH-19-121

Early Screening for Autism Spectrum Disorder (R21 Clinical Trial Not Allowed)

Closed on February 4, 2019.

Posted
October 25, 2018
Close date
February 4, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $499,500 in first-year total cost, median $249,750.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 BBBP-L (51)]2

Most frequent institutions

  1. CHILDREN'S HOSP OF PHILADELPHIA1
  2. UNIVERSITY OF CALIFORNIA AT DAVIS1
Competing awards under RFA-MH-19-121 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2019Novel computer vision-based assessment of infant-caregiver synchrony as an early level II screening tool for autism1R21HD102078-01SCHULTZ, ROBERT THOMASCHILDREN'S HOSP OF PHILADELPHIA, PA$264,000ZRG1
2019Development of a Telehealth Screener and Assessment for Infants at-risk for ASD in Diverse Communities.1R21HD100372-01TALBOTT, MEAGAN RUTHUNIVERSITY OF CALIFORNIA AT DAVIS, CA$235,500ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-MH-19-121: Early Screening for Autism Spectrum Disorder (R21 Clinical Trial Not Allowed) | ScienceDex | ConductScience